Quantitative μPET Imaging of Cerebral Glucose Metabolism and Amyloidosis in the TASTPM Double Transgenic Mouse Model of Alzheimer’s Disease

Author(s): Ann-Marie Waldron, Leonie Wyffels, Jeroen Verhaeghe, Astrid Bottelbergs, Jill Richardson, Jonathan Kelley, Mark Schmidt, Sigrid Stroobants, Xavier Langlois, Steven Staelens.

Journal Name: Current Alzheimer Research

Volume 12 , Issue 7 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Positron emission tomography studies of cerebral glucose utilization and amyloid-β deposition with fluoro-deoxy-D-glucose ([18F]-FDG) and amyloid tracers have shown characteristic pathological changes in Alzheimer’s Disease that can be used for disease diagnosis and monitoring. Application of this technology to preclinical research with transgenic animal models would greatly facilitate drug discovery and further understanding of disease processes. The results from preclinical studies with these imaging biomarkers have however been highly inconsistent, causing doubts over whether animal models can truly replicate an AD-like phenotype. In this study we performed in vivo imaging with [18F]-FDG and [18F]-AV45 in double transgenic TASTPM mice, a transgenic model that been previously demonstrated high levels of fibrillar amyloid-β and decreases in cerebral glucose utilization with ex vivo techniques. Our results show widespread and significant retention of [18F]-AV45 (p < 0.0001) in aged TASTPM mice in addition to significantregional decreases in [18F]-FDG uptake (p < 0.05). In vivo quantification of amyloid-β showed a strong (Pearson’s r = 0.7078), but not significant (p = 0.1156), positive correlation with ex vivo measures suggesting some limitations on tracer sensitivity. In the case of [18F]-FDG, voxelwise analysis greatly enhanced detection of hypometabolic regions. We further evidenced modest neuronal loss (thalamus p = 0.0318) that could underlie the observed hypometabolism. This research was performed in conjunction with the European Community's Seventh Framework Program (FP7/2007-2013) for the Innovative Medicine Initiative under the PharmaCog Grant Agreement no.115009.

Keywords: [18F]-AV45, [18F]-FDG, animal models, Alzheimer’s Disease, biomarker, positron emission tomography.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 7
Year: 2015
Page: [694 - 703]
Pages: 10
DOI: 10.2174/1567205012666150710104713
Price: $58

Article Metrics

PDF: 28